surmount-1 trial tirzepatide obesity without diabetes weight loss SURMOUNT 1 // Three-Year Obesty & Prevention Outcomes tirzepatide trial obesity without diabetes

They found that both methods effectively reduced body weight, with participants losing around 5.5 to 6.5 kilograms (roughly 12 to 14 pounds) after six months

Between the lines: GLP-1 drugs like Ozempic and Mounjaro are usually covered by insurance when used to treat Type 2 diabetes but many doctors also prescribe them off-label for overweight and obesity, which often isn't covered

Footnotes Author Contributions: Conceptualization: CEE, LA, MFL, HCB & EJ

At this time our providers believe that the use of this medication works best in conjuncture with added B12

It is also being approved for Migraine, cervical dystonia and TMJ (jaw grinding)

Abstract Background Limited data are available on the risk of pancreatic adverse events among people with obesity or type 2 diabetes mellitus (T2DM) initiating glucagon-like peptide-1 receptor agonist (GLP-1 RA)